To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, ...

Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.

The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.

The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for ...

Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research ...

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Prime Medicine, Inc.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

During Q2 2024, the Lazard Global Managed Volatility Equity Portfolio underperformed the MSCI World Index (net of fees).

MM+M’s 2024 Healthcare Marketers Trend Report reveals that AI and tech are top of mind for healthcare marketers. In this recent #TrendTalks session titled “The Ideal Customer Experience Across the ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- ...